Compare Amgen, Inc. (AMGN) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs ON Holding AG — how do they compare? Amgen, Inc. trades at $415.07 (market cap $224.14B), while ON Holding AG trades at $31.13 (market cap $10.33B). The key difference: Amgen, Inc. is far larger — about 21.7× ON Holding AG's market cap, and Amgen, Inc. pays a 2.43% dividend while ON Holding AG pays none. Which is the better fit depends on your goals.
| AMGN | ONON | |
|---|---|---|
Market Cap | $224.14B | $10.33B |
Sector | Health | Technology |
52-Week High | $417.20 | $50.63 |
52-Week Low | $271.18 | $30.91 |
Enterprise Value | $267.45B | $9.47B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
ONON shares plunged 19.52% to $31.21 after Q2 2026 earnings revealed a rare revenue miss and reduced full-year growth guidance, despite beating EPS estimates. The stock now trades near key support at $30 with bearish technical indicators dominating. Fundamentally, the company maintains strong profitability with 64.82% gross margins and 23.95% ROE, but wholesale channel weakness and cautious consumer spending have tempered growth expectations.
While current valuation multiples appear reasonable (P/E 21.17, P/S 5), the stock faces near-term headwinds from growth deceleration. Analyst consensus remains bullish with a $52.86 price target representing 69% upside, but investors should monitor Q3 earnings execution and wholesale recovery for confirmation of the investment thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
